-+ 0.00%
-+ 0.00%
-+ 0.00%

Equillium Announced That Ono Pharmaceutical Has Made The Strategic Business Decision To Allow Its Option To Acquire Equillium's Rights To Itolizumab To Expire

Benzinga·10/31/2024 11:45:22
Listen to the news
  • Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire
  • Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025
  • Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025